English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Atherosclerotic coronary disease is the most common pathological compromise of the heart of patients suffering from diabetes mellitus; this complication has led to the necessary estimation of global cardiovascular risk in patients with diabetes mellitus to be able to perform a better therapeutic inter- vention and thus reduce the incidence of microvascular and macrovascular complications that includes the selected variable, acute myocardial infarction. The therapeutic intervention includes treatment with angiotensin converting enzyme inhibitors that, according to studies, should be considered first of all in patients with acute myocardial infarction and with diabetes mellitus, thus the implementation of this pharmacological family is a choice and constitute the first line treatment in secondary prevention for the mentioned parients. The level of existing scientific evidence on the action of angiotensin converting enzyme inhibitors to reduce the risk of suffering a cardiovascular event should be assessed, since this acute condition often occurs and leads to death before to provide the required attention. An exhaustive review of the literature was carried out and the most relevant references were cited, to allowed for a descriptive bibliographic review of the angiotensin converting enzyme inhibitors.

INHIBIDORES DE ENZIMA CONVERTIDORA DE ANGIOTENSINA DISMINUYENDO RIESGO DE INFARTO AGUDO DE MIOCARDIO EN DIABÉTICOS